Skip to main content
Smart Investors Daily
VS

NASDAQ · VSTM

Verastem, Inc.

Healthcare · Biotechnology

$6.86

Down-$0.01 (-0.15%)

Updated Nov 20, 2026, 2:37 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
571.48M
P/E ratio
-3.75
Dividend yield
0.00%
52-week range
$3.43 – $10.82
Volume
3.72M
Avg. volume
2.24M

Price performance · VSTM

VSTM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

VSTM closed at $6.86 after 21 trading sessions, down 31.81% for the selected period.

Last close
$6.86
Period change
-31.81%
Period low
$6.86
Period high
$10.10
Daily close
View OHLC price history
VSTM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$6.90$7.20$6.8142$6.863.72M
Nov 18, 2026$7.35$7.55$6.78$6.873.98M
Nov 17, 2026$7.73$7.89$7.355$7.412.87M
Nov 16, 2026$8.18$8.30$7.685$7.702.25M
Nov 13, 2026$8.40$8.40$7.981$8.181.72M
Nov 12, 2026$8.84$9.12$8.41$8.442.09M
Nov 11, 2026$8.80$9.22$8.67$9.092.56M
Nov 10, 2026$8.57$8.81$8.431$8.732.95M
Nov 9, 2026$8.47$8.89$8.18$8.702.76M
Nov 6, 2026$8.66$8.86$7.72$8.417.04M
Nov 5, 2026$9.86$9.86$9.16$9.383.05M
Nov 4, 2026$10.00$10.10$9.422$9.852.51M
Nov 3, 2026$9.60$9.9589$9.60$9.772.75M
Nov 2, 2026$9.60$9.795$9.50$9.592.11M
Oct 30, 2026$9.63$9.92$9.50$9.752.41M
Oct 29, 2026$9.85$10.03$9.54$9.661.94M
Oct 28, 2026$10.10$10.25$9.78$9.8352.81M
Oct 27, 2026$9.945$10.15$9.76$10.104.71M
Oct 26, 2026$10.00$10.1625$9.3416$10.004.29M
Oct 23, 2026$10.085$10.22$9.71$10.043.76M
Oct 22, 2026$9.20$10.11$9.14$10.065.95M

Latest VSTM news

The latest Smart Investors Daily articles mentioning VSTM.

VSTM research

Overview

Company profile and research snapshot.

Company profile

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
VSTM recent ratings
DateFirmRatingTarget
Nov 6, 2026RBC CapitalOutperform—
Nov 6, 2026HC Wainwright & Co.Buy—
Oct 19, 2026BTIGBuy—
Oct 16, 2026MizuhoOutperform—
Oct 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 18, 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer

BOSTON, November 18, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung

Yahoo · Nov 16, 2026

Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance

Verastem (NASDAQ:VSTM) is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent launch as it awaits midstage trial results. At an investor discussion hosted by

Yahoo · Nov 14, 2026

Verastem (VSTM) Stock May Be Undervalued Despite VS7375 Progress

Verastem has offered a mixed ride for shareholders over the past few years, and that uneven share price record puts a simple question on the table for today. Is the current valuation of the stock properly anchored to the sales the biotech is generating right now? Over the last 5 years, Verastem has fallen 77.0%, which puts extra weight on whether the present market value lines up with what its sales can reasonably support. Progress on the VS7375 program and the US$250 million capital raise,...

Yahoo · Nov 13, 2026

Verastem Stock In Focus After Earnings Update And New Financing Plans

Verastem reported third quarter 2026 revenue of US$24.01 million and a net loss of US$74.72 million, alongside multiple new shelf registrations and a US$100 million at the market equity program. The combination of higher reported revenue, a smaller quarterly loss and fresh capital access suggests a business tightening operations while preparing to fund future oncology programs. We will now look at how Verastem's investment narrative is affected by this mix of improved earnings and sizable at...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.